Eftil

Quick links to important sections

Eftil

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eftil

What is Eftil? Definition, Type, and Composition

Property Description
Active ingredient Valproic Acid (also Valproate sodium or Divalproex sodium)
Form Capsules, syrups, and tablets (immediate, delayed, or extended-release)
Pharmacological class Anticonvulsant, Antiepileptic Drug (AED), Mood Stabilizer
General purpose Stabilization of nerve activity in the brain and nervous system
Origin Synthetic short-chain fatty acid derivative

Eftil is a prescription medicine containing the active substance Valproic Acid, a compound also utilized in its salt forms, such as Valproate sodium or Divalproex sodium. Chemically, it is classified as a synthetic short-chain fatty acid derivative, a unique classification that separates it from other major classes of older antiepileptic agents. The medicine functions as a single active ingredient product, relying solely on the multifaceted actions of Valproic Acid to stabilize neural activity, a property clinically recognized across numerous neurological disorders.

Eftil's Pharmacological Class and General Purpose

The drug belongs to the Anticonvulsant pharmacological class, also known as Antiepileptic Drugs (AEDs), and is also recognized as a primary Mood Stabilizer. Pharmacological studies have supported its ability to moderate brain signaling, affirming its general therapeutic purpose: promoting stability and managing patterns of abnormal, excessive electrical overactivity within the central nervous system. This dual classification reflects its ability to manage both rapid neurological firing and severe mood fluctuations.

Available Types: Dosage Forms and Preparation

Valproic Acid is prepared in multiple dosage forms, primarily for oral use, including standard capsules, syrups (oral liquid), and various types of tablets, such as delayed-release and extended-release formulations. It is also available as an intravenous solution for non-oral administration in clinical settings. The availability of forms like the syrup and liquid allows for easier administration to pediatric patients or others who may have difficulty swallowing solid tablets, providing necessary versatility in patient care.

Regulatory References

  1. Valproic Acid Drug Label

What side effects are possible with Eftil?

Possible Side Effects and Safety Information

The safety profile for Eftil (Valproic Acid) is officially documented by regulatory agencies and includes adverse reactions classified by frequency and affected physiological systems. This information is critical for understanding the medicine's risk profile.


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their rate of occurrence as defined in regulatory documents, such as the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Classification Examples of Documented Effects System-Organ Class Involved
Very Common / Common Nausea, Tremor, Weight gain, Somnolence, Thrombocytopenia (low platelet count), Hair loss (Alopecia) Gastrointestinal, Nervous system, Metabolism, Blood
Uncommon / Rare Hepatic injury (liver injury), Pancreatitis, Severe skin reactions (SJS, TEN, DRESS) Hepatobiliary, Gastrointestinal, Skin

Serious Safety Considerations

Regulatory agencies highlight specific, potentially life-threatening adverse reactions. These include a documented risk of Severe Hepatic Failure and Pancreatitis, which can be fatal. The label also notes the risk of Suicidal Ideation and Behavior associated with Antiepileptic Drugs, and a significant risk of Teratogenicity (harm to the unborn child) when used during pregnancy.


Population and Time-Related Patterns

The risk profile is not uniform. The highest risk of severe Hepatic Failure is generally reported during the first six months of treatment. Tremor and Thrombocytopenia may be related to the administered dose. Furthermore, specific safety constraints exist for pregnant women/women of childbearing potential (contraindicated for migraine prophylaxis) and for children under two years old, who have an increased risk of fatal liver injury. Use is also restricted in patients with pre-existing Hepatic Impairment or specific metabolic disorders like Urea Cycle Disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Valproic Acid (Eftil) may present with severe clinical manifestations that require immediate medical attention, as documented in regulatory information. The central nervous system (CNS) is primarily affected, with symptoms ranging from profound drowsiness and lethargy to stupor and ultimately coma. A critical sign is respiratory depression, which necessitates prompt life support measures. Other documented manifestations include hypotension (low blood pressure), tachycardia, and miosis (pinpoint pupils).

Life-threatening outcomes officially associated with severe toxicity include hyperammonemic encephalopathy, cerebral edema, and severe metabolic acidosis. Fatal outcomes linked to hepatotoxicity (liver damage) and pancreatitis have also been reported, underscoring the severity of acute overdose.

Regulatory guidance requires immediate medical attention for suspected overdose or when symptoms like unexplained abdominal pain, vomiting, or deep drowsiness occur. Initial emergency management focuses on medical stabilization. Procedures described in official labeling include enhanced elimination methods such as hemodialysis, which is required for life-threatening cases, and gastrointestinal decontamination (e.g., gastric lavage or activated charcoal). Monitoring of blood ammonia levels and ECG is necessary for assessing toxicity severity.

Therapeutic Uses of Eftil

Eftil, which contains valproate, is a medication applied across domains where additional symptomatic support is needed, primarily for conditions involving episodic or fluctuating manifestations. The medication is commonly used to help with specific symptom clusters, which include complex partial seizures and simple and complex absence seizures that may be part of the manifestations of epilepsy.

It is also considered relevant for easing the manic or mixed episodes associated with bipolar disorder, a condition characterized by periods of heightened symptoms. Furthermore, it may assist with the prophylaxis of migraine headaches, helping address symptom clusters that may become intense or disruptive.

The primary therapeutic areas where this medicine is considered relevant include epilepsy, bipolar disorder, and migraine prophylaxis. The use of this treatment provides support that helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms.

“This medication contributes to improved comfort and supports general well-being during symptomatic phases that interfere with daily functioning.”

Quick Fact: Supports the management of symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Eftil

Official regulatory documents define strict criteria for the use of Eftil (Valproate), primarily based on age, organ function, and reproductive status.

Category Regulatory Status Constraint Details
Contraindicated Populations Absolute Prohibition Patients with Hepatic Disease or significant hepatic dysfunction; those with known Urea Cycle Disorders (UCDs), Porphyria, or specific Mitochondrial Disorders (POLG mutations) [1.1, 3.1].
Age-Related Use Restricted/Not Established Adults are generally eligible. Children under 10 years are not established for epilepsy, and those under 12 years are not established for migraine prophylaxis. Use in children under 2 years carries a risk of fatal hepatotoxicity and requires extreme caution [4.4, 4.5].
Pregnancy and WOCBP Strictly Contraindicated/Restricted Pregnant women are contraindicated for migraine prophylaxis. For epilepsy/bipolar disorder, use is contraindicated unless no suitable alternative exists. Women of Childbearing Potential (WOCBP) must be on a Pregnancy Prevention Programme (PPP) and use effective contraception [1.2, 2.5].

Eligibility for Eftil is therefore defined by stringent regulations that prohibit its use in cases of underlying metabolic and liver conditions. Use is permitted only for adults and children ge 10 years for approved indications, and its use in WOCBP is conditional upon adherence to mandated risk minimization measures.

What should I know about interactions with other medicines?

Eftil Interactions with other medicines and products

Official regulatory information documents several clinically significant interactions for medicines containing Valproate, the active ingredient in Eftil. These interactions generally fall into two categories: those that modify drug exposure and those that increase the risk of specific toxic effects.

Interaction Type Interacting Substances (Examples) Official Regulatory Effect
Prohibited Combination Carbapenem Antibiotics (e.g., Meropenem) Co-administration results in a rapid and substantial reduction in Valproate plasma concentrations, risking loss of therapeutic control.
Exposure Modifiers (Decrease) Hepatic Enzyme Inducers (e.g., Phenytoin, Carbamazepine, Rifampin) These substances officially increase Valproate clearance, leading to decreased Valproate plasma levels.
Exposure Modifiers (Increase) Felbamate, Aspirin (via protein binding) These agents are documented to decrease Valproate clearance or displace protein binding, resulting in increased Valproate plasma concentrations.
Co-Drug Exposure Increase Lamotrigine, Phenytoin, Ethosuximide Valproate officially inhibits the metabolism of these co-administered drugs, increasing their respective plasma concentrations.
Additive Toxicity Topiramate, Alcohol Topiramate co-administration is associated with an increased risk of hyperammonemia and encephalopathy. Alcohol may increase nervous system side effects like somnolence.

Regulatory documents specify that the risk of fatal hepatotoxicity is considerably increased in children under the age of two years when treated with multiple anticonvulsants.

Monitoring of Valproate and concomitant drug concentrations is officially indicated whenever enzyme-inducing or inhibiting medicines are introduced or withdrawn.

Mechanism of Action

The mechanism of Eftil (Valproic Acid) is defined by a versatile, multi-target action within the central nervous system, combining immediate electrical dampening with slower, long-term modulation of signaling pathways.

Enhanced Inhibitory Neurotransmission

This domain involves augmenting the brain’s primary dampening system by acting on enzymes that regulate the inhibitory neurotransmitter, Gamma-Aminobutyric Acid ( GABA). Eftil enhances the synthesis of GABA while simultaneously slowing its breakdown by inhibiting GABA Transaminase. This combined action increases the functional availability of GABA, raising the threshold for nerve firing, which promotes a reduced susceptibility to electrical discharge at the nerve membrane.

Direct Modulation of Neuronal Excitability

Eftil directly interferes with the electrical signals required to generate nerve impulses. It modulates Voltage-Gated Sodium Channels ( VGSCs), suppressing the intense, sustained Na^+ current that drives rapid firing. Additionally, it inhibits T-type Calcium Channels in the thalamus, interfering with rhythmic firing patterns. This direct action on ion flow contributes to attenuated high-frequency neuronal firing and suppression of rapid electrical discharge patterns in neural circuits.

Epigenetic Regulation of Signaling Pathways

Beyond acute electrical effects, the drug engages mechanisms for long-term cellular functional regulation by inhibiting Histone Deacetylases (HDACs). This enzymatic inhibition alters the transcription of specific genes related to neuronal function and signaling cascades. This mechanism supports long-term functional regulation in the organization and communication of nerve circuits, complementing the drug's rapid electrophysiological effects.

Dosage and Administration Information

How Eftil is Used: Official Administration Guidelines

Eftil, containing the active substance Valproic Acid, is administered according to specific principles defined in official regulatory labeling. The primary route is oral, though an Intravenous (IV) solution is available for temporary use when oral intake is not feasible.

Official Dosing and Frequency

Treatment is typically initiated at low doses and gradually increased through a process called titration.

Indication (Adults) Starting Dose Maximum Recommended Dose
Epilepsy 10 to 15 mg/kg/day (oral) 60 mg/kg/day
Mania 750 mg/day or 25 mg/kg/day (oral) 60 mg/kg/day

Oral doses are typically increased in increments of 5 to 10 mg/kg/day at 1-week intervals until an optimal clinical response is achieved. Forms that are not extended-release (ER) must be given in divided doses if the total daily dose is greater than 250 mg, while ER tablets are administered once a day.

Administration Rules and Procedural Constraints

  • Intake: The medicine may be taken with or after food to mitigate potential gastrointestinal irritation.
  • Handling: Delayed-Release and Extended-Release tablets must be swallowed whole and must not be crushed or chewed, as this alters the drug's release characteristics. Capsule contents (Sprinkle forms) may be opened and mixed with a small amount of soft food, such as applesauce, and consumed immediately.
  • IV Use: The intravenous solution must be diluted prior to use and administered as a slow infusion, usually over a minimum of 60 minutes. The use of the IV form is intended for short-term substitution when the oral route is not possible.
  • Population Adjustments: For older adults (geriatric), regulatory guidelines recommend initiating therapy at a reduced starting dose and utilizing a slower pace for any subsequent dose increases.

Recent Clinical Evidence

Recent Clinical Evidence

Research surrounding the compound has primarily focused on studies in chronic neurological conditions, specifically focusing on research topics related to the compound's observable effects on symptom presentation.


Major Findings on Efficacy

Effects on Neural Activity

Research has explored the evaluation of neuronal excitability in in vitro and animal models of chronic pain. Early laboratory studies examined nerve signal transmission parameters. This research investigated measures related to paroxysmal episode severity following administration of the compound, with one study reporting a range of changes in patient-reported severity scores.

Symptom Parameters

Several Phase 3 trials evaluated the compound in participants with nerve disorders to study changes in symptoms. These studies generally examined measured parameters related to the speed and intensity of symptoms, like localized discomfort and involuntary movements. One study observed changes in episode frequency over a period of 12 weeks among the trial participants.


Research in Specific Patient Groups

Co-existing Conditions

Clinical trials included a patient population with certain pre-existing cardiac conditions. Exclusion criteria in most studies involved participants who also had uncontrolled autoimmune disorders.

Polypharmacy and Co-Administration

Studies explored whether co-administration altered clinical parameters when the compound was studied alongside common antiepileptic drugs (AEDs). Trials reported findings related to the combined therapies' effects on plasma concentrations of both the study compound and the co-administered AEDs.


Ongoing Research Direction

The compound is a substance that has been the subject of several contemporary studies, with a current focus on its potential study in a wider range of sensory neuropathy disorders. Further large-scale studies are being planned to gather more data on long-term patient outcomes and pharmacoeconomics. Research is also evaluating the compound in study populations experiencing nerve pain following prior use of first-line agents.

Frequently Asked Questions (FAQ)

Common questions about Eftil (FAQ)


Q: How quickly should I expect to feel the effects of Eftil after starting it?

Regulatory information indicates that the dose is increased gradually, usually in weekly intervals, until a clinically appropriate response is achieved. This suggests that the full effects may require a period of adjustment after starting the medication.

Q: What is the typical timeframe for seeing the full benefits of Eftil?

Official labeling states that the dose is adjusted over a period of weeks to reach a level that supports a therapeutic effect. This process aligns with the titration schedule outlined in the prescribing information.

Q: Can Eftil be crushed or split if it's a tablet?

Delayed-release and extended-release tablets must be swallowed whole and must not be crushed or chewed, as this alters the drug's release characteristics. However, the contents of capsule (Sprinkle) forms are permitted to be opened and mixed with a small amount of soft food for immediate consumption, as specified by the manufacturer.

Q: Can a sudden stop of Eftil cause any problems or withdrawal effects?

Official warnings state that abrupt discontinuation should be avoided, especially in patients treated for seizures. Regulatory warnings indicate that stopping the medication suddenly may precipitate status epilepticus (a condition involving continuous seizures).

Q: What are the main benefits of the extended-release formula of Eftil?

The primary benefit noted in official product information is that the extended-release formulation is administered once a day, which may simplify the daily dosing schedule compared to immediate-release forms.

Q: Can Eftil be used long-term, or is it typically a short-course treatment?

For the treatment of manic episodes, controlled clinical trials have not demonstrated efficacy for use longer than three weeks. Therefore, regulatory documents advise that the risks and benefits of extended use must be continually reevaluated by a healthcare professional.

Q: What kind of follow-up is necessary after starting Eftil?

Official safety precautions mandate the monitoring of laboratory values, including liver function tests, platelet counts, and blood ammonia levels, especially during the first six months of treatment. This monitoring is required to detect certain adverse reactions early.

Q: What information should I have ready for my doctor before discussing Eftil?

Official labeling requires knowledge of any history of liver disease, a metabolic disorder called Urea Cycle Disorders, or a family history of POLG gene mutations, as these conditions are contraindications or require precautions. Sharing this information allows the healthcare provider to assess appropriateness.

Q: Can Eftil cause weight gain, and if so, how common is it?

Yes, official drug safety information lists weight gain as a common adverse reaction that has been reported in clinical trials.

Q: Is it normal to feel tired or drowsy when first starting Eftil?

Yes, Somnolence (drowsiness or sleepiness) is listed in regulatory documents as a very common side effect. This effect is often reported when treatment is first initiated or during dose adjustments.

Q: Does Eftil affect my ability to concentrate or remember things?

Official adverse reaction reports indicate that both abnormal thinking and amnesia (memory loss) are listed as common side effects associated with the use of Eftil.

Q: Can Eftil cause hair loss, and is it reversible?

Yes, Alopecia (hair loss) is listed as a common adverse reaction in official safety documents. Although hair loss is common, official safety information does not specify if the effect is reversible.

Q: Can Eftil affect a person's mood or cause mood swings?

The drug is associated with a regulatory warning for an increased risk of suicidal thoughts or behavior. Less severe adverse reactions like emotional lability and abnormal thinking are also listed in official reports.

Q: What are the signs of a serious, but rare, side effect from Eftil?

Regulatory documents list symptoms that may indicate serious problems, such as unexplained fever, weakness, vomiting, swelling of the face, dark urine, or changes in mental status. These symptoms require prompt professional evaluation.

Q: What should I do if the side effects of Eftil become bothersome?

Official warnings advise that serious symptoms, such as unexplained lethargy or vomiting, require prompt evaluation by a healthcare provider. Patients are generally advised to discuss all bothersome side effects with their healthcare team.

Q: What are the signs that Eftil might not be working for me?

In official warnings regarding liver safety, loss of seizure control is cited as a non-specific symptom that may precede serious hepatotoxicity. Discussing any change in symptoms or control with a healthcare professional is important.

Q: Is Eftil known to cause any skin reactions or rashes?

A generalized rash is a reported adverse reaction. Official documents also note the occurrence of rare, severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Q: Are there any specific foods or drinks I need to avoid while on Eftil?

Official safety documents advise caution with alcohol consumption. Alcohol can increase central nervous system side effects such as dizziness and drowsiness, which are also side effects of the medication itself.

Q: Is Eftil safe to drive or operate machinery while taking Eftil?

Because Eftil can cause drowsiness and dizziness (CNS depression), regulatory information states that patients should be cautioned against operating hazardous machinery, including automobiles, until it is known how the medication affects them.

Q: Does Eftil interact with oral contraceptives or hormone replacement therapy?

Regulatory information indicates that valproate may potentially decrease the serum concentration of the hormones in contraceptives. Due to the high risk of birth defects, women of childbearing potential are required to use effective contraception while taking Eftil.

Q: Can older adults safely take Eftil, and are there special precautions?

Yes, but official guidelines recommend special precautions. For older adults, the initial starting dose should be reduced, and any subsequent dose increases should be done more slowly, with close monitoring for adverse reactions like drowsiness.

Q: Can men taking Eftil have any reproductive side effects?

Official reports indicate that infertility in men has been associated with valproate. Additionally, regulatory advice notes that there may be a potential risk of neurodevelopmental disorders in children born to men treated with valproate during the three months before conception.

Q: What are the potential effects of Eftil on kidney health?

Official documents warn that Valproate has been linked to rare but serious multi-organ hypersensitivity reactions (DRESS syndrome), which may affect various organs, including the kidneys.

Q: What happens if I miss a dose of Eftil?

According to the patient information leaflet, if a dose is missed, it should be taken as soon as possible unless it is near the time of the next scheduled dose. Patients are cautioned not to take two doses together to make up for a missed dose.

Q: What does the medical evidence say about the long-term safety of Eftil?

Official information on long-term use, particularly in certain conditions like mania, indicates that efficacy beyond three weeks has not been established in controlled trials. Therefore, the necessity for continued treatment must be regularly reviewed by a doctor.

How should Eftil be stored and disposed of?

Eftil (valproate semisodium) must be stored and handled according to specific conditions detailed in official regulatory labeling.

Storage Requirements

The medication must be stored at Controlled Room Temperature, typically between 20 to 25 C (68 to 77 F). It is essential to protect the product from moisture and humidity. The container must be kept tightly closed, and for some oral forms, the tablets should not be removed from the original blister foil until immediately before administration to maintain stability.

Safety and Disposal

Eftil must be stored out of the sight and reach of children.

To dispose of unused or expired medicine, regulatory agencies advise using a drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and sealed in a bag for household trash. The product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eftil found in:

A-Z Index: